Passage of VIP/PACAP/secretin family across the blood-brain barrier: Therapeutic effects

被引:97
作者
Dogrukol-Ak, D [1 ]
Tore, F
Tuncel, N
机构
[1] Anadolu Univ, Fac Pharm, Dept Analyt Chem, TR-26470 Eskisehir, Turkey
[2] Abant Izzet Baysal Univ, Fac Med, Dept Physiol, TR-14280 Bolu, Turkey
[3] Osmangazi Univ, Fac Med, Dept Physiol, TR-26480 Eskisehir, Turkey
关键词
D O I
10.2174/1381612043384934
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, VIP/PACAP/secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP(1)), GLP(2), gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and ill various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. Oil the other hand, some of the members of this family that present in the brain, call cross from brain to blood and reach the peripheral tat-gets. VIP, secretin, GLP(1), and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP(2) and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP/PACAP/secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits ill various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.
引用
收藏
页码:1325 / 1340
页数:16
相关论文
共 183 条
[81]  
Hashimoto H, 1996, J COMP NEUROL, V371, P567
[82]  
HORWATH K, 1998, J ASS ACAD MINOR PHY, V9, P9
[83]   Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier [J].
Huber, JD ;
Egleton, RD ;
Davis, TP .
TRENDS IN NEUROSCIENCES, 2001, 24 (12) :719-725
[84]   Is there a basis for novel pharmacotherapy of autism? [J].
Hunsinger, DM ;
Nguyen, T ;
Zebraski, SE ;
Raffa, RB .
LIFE SCIENCES, 2000, 67 (14) :1667-1682
[85]   FUNCTIONAL EXPRESSION AND TISSUE DISTRIBUTION OF A NOVEL RECEPTOR FOR VASOACTIVE INTESTINAL POLYPEPTIDE [J].
ISHIHARA, T ;
SHIGEMOTO, R ;
MORI, K ;
TAKAHASHI, K ;
NAGATA, S .
NEURON, 1992, 8 (04) :811-819
[86]   DISTRIBUTION OF GLUCAGONLIKE PEPTIDE-I (GLP-I), GLUCAGON, AND GLICENTIN IN THE RAT-BRAIN - AN IMMUNOCYTOCHEMICAL STUDY [J].
JIN, SLC ;
HAN, VKM ;
SIMMONS, JG ;
TOWLE, AC ;
LAUDER, JM ;
LUND, PK .
JOURNAL OF COMPARATIVE NEUROLOGY, 1988, 271 (04) :519-532
[87]  
Johanson C. E., 1995, NEUROSCIENCE MED, P171
[88]   DIFFERENTIAL CLEARANCE OF NEUROPHYSIN AND NEUROHYPOPHYSEAL PEPTIDES FROM THE CEREBROSPINAL-FLUID IN CONSCIOUS GUINEA-PIGS [J].
JONES, PM ;
ROBINSON, ICAF .
NEUROENDOCRINOLOGY, 1982, 34 (04) :297-302
[89]  
KALFIN R, 1994, J PHARMACOL EXP THER, V268, P952
[90]   Prevention of cerebral vasospasm by vasodilatory peptide maxadilan following subarachnoid hemorrhage in rabbits [J].
Kaminuma, T ;
Shimizu, H ;
Ahmad, I ;
Ochiai, N ;
Ehama, R ;
Ohnuma, M ;
Banba, T ;
Watabe, K ;
Lerner, EA ;
Imaizumi, S ;
Tajima, M ;
Yoshimoto, T .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :71-80